<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009017</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2863</org_study_id>
    <nct_id>NCT05009017</nct_id>
  </id_info>
  <brief_title>Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients</brief_title>
  <official_title>The Safety Study of Bevacizumab Biosimilars in the Real World</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monoclonal antibody drugs are expensive, and the listing of biosimilar drugs can help&#xD;
      increase the availability and lower prices of biologic drugs, and can better meet the&#xD;
      public's demand for biotherapeutic products. The first bevacizumab biosimilar in China was&#xD;
      launched in December 2019. Although monoclonal antibody biosimilar drugs are similar to the&#xD;
      original drug in terms of quality, safety and effectiveness, their production process may be&#xD;
      different from the original drug, and their clinical application cannot be completely&#xD;
      equivalent to the original drug. Especially after the market is applied to a wider patient&#xD;
      population, the safety and effectiveness are more worthy of attention. This study started&#xD;
      from the perspective of pharmacy. Three hospitals in China participated in the real-world&#xD;
      safety assessment of bevacizumab biosimilars. An observational cohort study design was&#xD;
      adopted to include all cases of lung cancer and colorectal cancer using bevacizumab&#xD;
      biosimilars and original drugs during the study period, and the propensity score matching was&#xD;
      used to reduce the influence of confounding factors and conduct safety assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>12 months</time_frame>
    <description>Severity of adverse drug reactions</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Biosimilar</condition>
  <arm_group>
    <arm_group_label>Biosimilar group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Originator group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab</description>
    <arm_group_label>Biosimilar group</arm_group_label>
    <arm_group_label>Originator group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients in 3 study hospitals diagnosed with non-small cell lung cancer or colorectal&#xD;
        cancer using originator or biosimilar of bevacizumab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ①Inpatients diagnosed with non-small cell lung cancer or colorectal cancer;&#xD;
             ②Bevacizumab biosimilars or original drugs were used for treatment during the study&#xD;
             period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ①Age&lt;18 years old; ②Person who has used bevacizumab within six months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guohui Li, Bachelor</last_name>
    <phone>01087788578</phone>
    <email>lgh0603@cicams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guohui Li</last_name>
      <phone>010-87788577</phone>
      <email>lgh0603@cicams.ac.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenzhou Zhang</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenzhou Zhang, Master</last_name>
      <phone>0371-65587320</phone>
      <email>wenzhouzhang@zzu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Guohui Li</investigator_full_name>
    <investigator_title>Pharmacy</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

